[CYTK] Cytokinetics, Incorporated


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 384.31 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 12.4 Change: 0.6 (5.08%)
Ext. hours: Change: 0 (0%)

chart CYTK

Refresh chart

Strongest Trends Summary For CYTK

CYTK is in the long-term down -55% below S&P in 2 years and down -98% below S&P in 21 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Cytokinetics, Incorporated, a clinical stage biopharmaceutical company, focuses on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the treatment of heart failure. The company holds a license to develop and commercialize omecamtiv mecarbil and related compounds worldwide. It develops tirasemtiv, a fast skeletal muscle activator, as a potential treatment for diseases and medical conditions associated with neuromuscular dysfunction. Tirasemtiv is in Phase II clinical trials program and has been granted orphan drug designation and fast track status by the United States Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis. Cytokinetics, Incorporated has a st

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding39.62 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -43.32% Sales Growth - Q/Q-79.71% P/E
P/E To EPS Growth P/S8.86 P/BV4.57 Price/Cash Per Share3.56
Price/Free Cash Flow-8.36 ROA-12.09% ROE-17.56% ROI
Current Ratio4.37 Quick Ratio Long Term Debt/Equity Debt Ratio0.3
Gross Margin Operating Margin-34.34% Net Profit Margin-34.06% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities70 K Cash From Investing Activities-32.09 M Cash From Operating Activities34.36 M Gross Profit
Net Profit-8.87 M Operating Profit-8.91 M Total Assets122.21 M Total Current Assets110.81 M
Total Current Liabilities25.39 M Total Debt Total Liabilities38.06 M Total Revenue4.41 M
Technical Data
High 52 week15.65 Low 52 week6.4 Last close7.9 Last change0%
RSI72.97 Average true range0.35 Beta1.31 Volume193.45 K
Simple moving average 20 days9.04% Simple moving average 50 days0.07% Simple moving average 200 days-4.96%
Performance Data
Performance Week8.97% Performance Month23.44% Performance Quart-11.73% Performance Half-5.95%
Performance Year-46.44% Performance Year-to-date-3.07% Volatility daily2.58% Volatility weekly5.77%
Volatility monthly11.83% Volatility yearly40.99% Relative Volume217.31% Average Volume326.47 K
New High New Low


2019-03-18 16:00:00 | Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at ACC.19

2019-03-11 16:04:38 | Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at ACC.19

2019-03-07 16:10:27 | Cytokinetics Announces Presentation of Results From FORTITUDE-ALS at the American Academy of Neurology 71st Annual Meeting

2019-03-07 10:38:02 | Some Cytokinetics Shareholders Are Down 43%

2019-03-07 06:48:03 | Cytokinetics Inc CYTK Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-02-28 07:30:00 | Cytokinetics Joins Global Initiative To Recognize International Rare Disease Day

2019-02-22 16:53:09 | Amgen Starts Phase III Enrollment for Heart Failure Drug

2019-02-22 01:46:10 | Edited Transcript of CYTK earnings conference call or presentation 21-Feb-19 9:30pm GMT

2019-02-21 22:18:06 | Cytokinetics Inc CYTK Q4 2018 Earnings Conference Call Transcript

2019-02-21 17:15:10 | Cytokinetics CYTK Reports Q4 Loss, Tops Revenue Estimates

2019-02-21 16:11:29 | Cytokinetics: 4Q Earnings Snapshot

2019-02-21 16:00:00 | Cytokinetics Reports Fourth Quarter 2018 Financial Results

2019-02-21 08:30:00 | Amgen, Cytokinetics and Servier Announce Start of METEORIC-HF, the Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure

2019-02-20 09:00:00 | Cytokinetics Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin Activator

2019-02-14 10:45:03 | The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna

2019-02-14 10:31:03 | Will Cytokinetics CYTK Report Negative Earnings Next Week? What You Should Know

2019-02-13 08:36:01 | 5 Tiny Biotech Stocks With Superb Growth Potential

2019-02-07 16:00:00 | Cytokinetics to Announce Fourth Quarter Results on February 21, 2019

2019-01-22 07:30:00 | Cytokinetics Announces Receipt of FDA Feedback Regarding Reldesemtiv in Patients With SMA

2019-01-04 07:24:12 | Could Cytokinetics, Incorporated’s NASDAQ:CYTK Investor Composition Influence The Stock Price?

2018-12-22 02:51:56 | Hedge Funds Are Dumping Cytokinetics, Inc. CYTK

2018-12-10 07:30:00 | Cytokinetics Announces New Data Presented at the International Symposium on ALS/MND

2018-12-05 07:30:00 | Cytokinetics Announces Initiation of Phase 1 Clinical Trial of CK-3773274, a Cardiac Myosin Inhibitor

2018-12-03 07:57:40 | Jim Cramer Gives His Opinion On Netflix, Kraft Heinz And More

2018-11-27 08:00:00 | Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

2018-11-27 07:30:00 | Cytokinetics Completes Enrollment in FORTITUDE-ALS, Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS

2018-11-26 16:00:00 | Cytokinetics Announces Five Presentations at the International Symposium on ALS/MND

2018-11-20 04:40:09 | Cytokinetics Sees Hammer Chart Pattern: Time to Buy?

2018-11-07 16:00:00 | Cytokinetics to Participate in Upcoming Investor Conferences

2018-11-02 00:10:49 | Edited Transcript of CYTK earnings conference call or presentation 1-Nov-18 8:30pm GMT

2018-11-01 17:10:09 | Cytokinetics CYTK Reports Q3 Loss, Tops Revenue Estimates

2018-11-01 16:08:20 | Cytokinetics: 3Q Earnings Snapshot

2018-11-01 16:00:00 | Cytokinetics, Inc. Reports Third Quarter 2018 Financial Results

2018-10-18 16:00:00 | Cytokinetics to Announce Third Quarter Results on November 1, 2018

2018-10-16 07:30:00 | Cytokinetics Unveils Expanded Development Pipeline and Provides Key Updates on Late-Stage Clinical Research Programs at R&D Day

2018-10-09 08:00:00 | Report: Developing Opportunities within Denny's, Cytokinetics, Beazer Homes, Heidrick & Struggles International, Equity Commonwealth, and Spok — Future Expectations, Projections Moving into 2018

2018-10-08 07:30:23 | The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs

2018-10-05 07:30:00 | Cytokinetics and Astellas Provide Updates Regarding Collaborative Skeletal Muscle Program

2018-10-02 16:00:00 | Cytokinetics to Host R&D Day on October 16, 2018

2018-10-01 09:46:45 | Cytokinetics Incorporated NASDAQ:CYTK: Risks You Need To Consider Before Buying

2018-09-25 16:00:00 | Cytokinetics to Present at the Cantor Fitzgerald Global Healthcare Conference

2018-09-21 15:32:22 | Cantor Fitzgerald's 7 Buys For 7 Biotechs

2018-09-16 14:22:16 | The Week Ahead In Biotech Sept. 16-22: Conferences, PDUFA Dates, Clinical Trial Results And IPOs

2018-09-05 16:00:00 | Cytokinetics to Present at the Morgan Stanley Global Healthcare Conference

2018-08-28 08:30:00 | Cytokinetics Awards Inaugural Communications Fellowship To The ALS Association Golden West Chapter

2018-08-01 09:39:50 | Cytokinetics Downgraded On Data Delay

2018-08-01 08:10:00 | Market Trends Toward New Normal in US Foods Holding, Limelight Networks, Ladenburg Thalmann Financial Services, MPLX LP, Cytokinetics, and FuelCell Energy — Emerging Consolidated Expectations, Analyst Ratings

2018-07-27 11:19:22 | Edited Transcript of CYTK earnings conference call or presentation 26-Jul-18 8:30pm GMT

2018-07-26 17:19:16 | Cytokinetics: 2Q Earnings Snapshot

2018-07-26 16:00:00 | Cytokinetics, Inc. Reports Second Quarter 2018 Financial Results